Cue Biopharma (CUE) Revenue & Revenue Breakdown
Cue Biopharma Revenue Highlights
Latest Revenue (Y)
$5.49M
Latest Revenue (Q)
$3.34M
Cue Biopharma Revenue by Period
Cue Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.49M | 340.88% |
| 2022-12-31 | $1.25M | -91.67% |
| 2021-12-31 | $14.94M | 373.68% |
| 2020-12-31 | $3.15M | -8.78% |
| 2019-12-31 | $3.46M | 202.64% |
| 2018-12-31 | $1.14M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Cue Biopharma generated $5.49M in revenue during NA 2023, up 340.88% compared to the previous quarter, and up 480.48% compared to the same period a year ago.
Cue Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $3.34M | 25.51% |
| 2024-06-30 | $2.66M | 54.80% |
| 2024-03-31 | $1.72M | -5.71% |
| 2023-12-31 | $1.82M | -13.29% |
| 2023-09-30 | $2.10M | 51.95% |
| 2023-06-30 | $1.38M | 639.04% |
| 2023-03-31 | $187.00K | 23.66% |
| 2022-12-31 | $151.23K | 122.39% |
| 2022-09-30 | $68.00K | 161.54% |
| 2022-06-30 | $26.00K | -97.40% |
| 2022-03-31 | $1.00M | -87.89% |
| 2021-12-31 | $8.25M | 244.65% |
| 2021-09-30 | $2.40M | -12.56% |
| 2021-06-30 | $2.74M | 76.37% |
| 2021-03-31 | $1.55M | 226.72% |
| 2020-12-31 | $475.32K | -32.48% |
| 2020-09-30 | $704.00K | -34.51% |
| 2020-06-30 | $1.07M | 19.44% |
| 2020-03-31 | $900.00K | -14.20% |
| 2019-12-31 | $1.05M | 6.61% |
| 2019-09-30 | $984.00K | -6.73% |
| 2019-06-30 | $1.05M | 185.14% |
| 2019-03-31 | $370.00K | 11.92% |
| 2018-12-31 | $330.60K | -26.37% |
| 2018-09-30 | $449.00K | 161.05% |
| 2018-06-30 | $172.00K | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | - |
Cue Biopharma generated $3.34M in revenue during Q3 2024, up 25.51% compared to the previous quarter, and up 241.39% compared to the same period a year ago.
Cue Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| COYA | Coya Therapeutics | $3.55B | - |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| FENC | Fennec Pharmaceuticals | $47.54M | $6.97M |
| CUE | Cue Biopharma | $5.49M | $3.34M |
| TCRX | TScan Therapeutics | $2.82M | - |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| INMB | INmune Bio | $14.00K | - |
| LTRN | Lantern Pharma | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ANIX | Anixa Biosciences | - | - |
| INAB | IN8bio | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| HOOK | HOOKIPA Pharma | - | $4.70M |
| DRMA | Dermata Therapeutics | - | - |
| PYPD | PolyPid | - | - |